Log in

Relevant bibliographies by topics / HR+/HER2− metastatic breast cancer / Journal articles

To see the other types of publications on this topic, follow the link: HR+/HER2− metastatic breast cancer.

Journal articles on the topic 'HR+/HER2− metastatic breast cancer'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'HR+/HER2− metastatic breast cancer.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Khan, Noman Ahmed Jang, Mahmoud Abdallah, and Maria Tria Tirona. "Hormone Receptor Positive/HER2 Negative Breast Cancer With Isolated Bladder Metastasis: A Rare Case." Journal of Investigative Medicine High Impact Case Reports 9 (January 2021): 232470962110221. http://dx.doi.org/10.1177/23247096211022186.

Full text

Abstract:

Breast cancer is the most common cancer diagnosed in women in North America. Hormone receptor positive (HR+) and HER2 negative (HER2−) breast cancers account for at least 60% to 70% of all breast cancer cases. They usually metastasize to lymph nodes, bones, liver, lungs, and brain. Urinary bladder is a very unusual site for metastatic HR+/HER2− breast cancer and occurs in only 2% of all metastatic disease. In this article, we present a case of a 63-year-old female with locally advanced breast cancer who underwent mastectomy, adjuvant chemotherapy, radiation, and hormonal therapy. She was in re

APA, Harvard, Vancouver, ISO, and other styles

2

Hrizat, A. S., and E. Brachtel. "Proliferation Index in “HER2 Low” Metastatic Breast Cancer." American Journal of Clinical Pathology 160, Supplement_1 (2023): S13—S14. http://dx.doi.org/10.1093/ajcp/aqad150.030.

Full text

Abstract:

Abstract Introduction/Objective There is considerable genetic heterogeneity between primary and metastatic breast cancer. The new classification of the "HER2-low" category includes tumors characterized by a low level of HER2 expression (immunohistochemistry (IHC) score 1+ or 2+ without in situ hybridization (ISH) amplification), in addition to the known HER2 negative (HER2-0) and HER2+ (amplified) cases. The Ki67 proliferation index (PI) can predict breast cancer prognosis. Proliferation changes in metastatic breast cancer and in different HER2 categories are not well delineated in clinical co

APA, Harvard, Vancouver, ISO, and other styles

3

Zhu, Anjie, and Hui-Ping Li. "Abstract PO2-05-13: HER2 status presented an unstable switching from primary to recurrent breast cancer." Cancer Research 84, no. 9_Supplement (2024): PO2–05–13—PO2–05–13. http://dx.doi.org/10.1158/1538-7445.sabcs23-po2-05-13.

Full text

Abstract:

Abstract Background: Breast cancer patients with HER2-2+ expression had heterogeneous characteristic. Treatment decision is of great importance after progression. Objective: We explored patients with HER2-2+ in matched primary or recurrent/metastatic tumor samples from January 2010 to June 2022 in our institute were included to evaluate the evolution from or to HER2-2+ expression. Meanwhile, with an emerging of novel entity as HER2-low expression breast cancer, we included this category when analysis as well. Results: In the cohort of a total of 159 breast cancer patients with HER2-2+ expressi

APA, Harvard, Vancouver, ISO, and other styles

4

Han, Yiqun, Yun Wu, Hangcheng Xu, Jiayu Wang, and Binghe Xu. "The impact of hormone receptor on the clinical outcomes of HER2-positive breast cancer: a population-based study." International Journal of Clinical Oncology 27, no. 4 (2022): 707–16. http://dx.doi.org/10.1007/s10147-022-02115-x.

Full text

Abstract:

Abstract Background To investigate the impact of hormone receptor (HR) on the clinicopathological characteristics and prognosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Methods Using the Surveillance, Epidemiology, and End Results database, we enrolled patients diagnosed with HER2-positive breast cancer between 2010 and 2016, which were successively assessed for eligibility and categorized into HR + /HER2 + and HR-/HER2 + subgroups. Clinicopathological characteristics were undergone comparative analyses with the baseline distinctions calibrated by propensity s

APA, Harvard, Vancouver, ISO, and other styles

5

Zhang, Shaohua, Tao Wang, Li Bian, Guohui Han, Xiangdong Bai, and Zefei Jiang. "Abstract P5-10-21: Efficacy and safety of utidelone plus bevacizumab in the treatment of patients with Her2- metastatic breast cancer study." Clinical Cancer Research 31, no. 12_Supplement (2025): P5–10–21—P5–10–21. https://doi.org/10.1158/1557-3265.sabcs24-p5-10-21.

Full text

Abstract:

Abstract Background: Despite the rapid development of targeted therapy and immunotherapy for breast cancer in recent years, Chemotherapy remains an important treatment for metastatic breast cancer (MBC), and currently there is no standard chemotherapy regimen for MBC patients previously treated with taxanes. Utidelone is a new microtubule inhibitor drug developed in China, which has demonstrated excellent efficacy for metastatic breast cancer. Historical studies have shown that chemotherapy combined with angiogenic inhibitors can improve PFS in advanced breast cancer patients compared with che

APA, Harvard, Vancouver, ISO, and other styles

6

Lv, Huimin, Min Yan, Mengwei Zhang, et al. "Abstract PO1-06-05: Heterogeneity and prognostic characteristics of HER2-low breast cancer: A retrospective analysis of patients with HER2-negative metastatic breast cancer." Cancer Research 84, no. 9_Supplement (2024): PO1–06–05—PO1–06–05. http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-06-05.

Full text

Abstract:

Abstract Background: It remains uncertain as to whether low levels of HER2 positivity have any prognostic implications in breast cancer patients, whether HER2 levels can be inconsistent between primary tumors and metastatic lesions in individuals with advanced HER2-negative breast cancer, and how such inconsistencies may impact patient prognosis. Methods: A retrospective analysis of advanced breast cancer patients admitted to our hospital from from January 1st, 2010 to January 1st, 2019 was performed, with all patients that underwent at least one metastatic lesion biopsy being screened. The ho

APA, Harvard, Vancouver, ISO, and other styles

7

Niikura, Naoki, Jun Liu, Naoki Hayashi, et al. "Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Metastatic Sites of HER2-Overexpressing Primary Breast Tumors." Journal of Clinical Oncology 30, no. 6 (2012): 593–99. http://dx.doi.org/10.1200/jco.2010.33.8889.

Full text

Abstract:

Purpose We evaluated whether patients with human epidermal growth factor receptor 2 (HER2) –positive primary breast tumors had metastatic tumors that were HER2 positive (concordant) or HER2 negative (discordant). We then evaluated whether treatment with trastuzumab or chemotherapy before biopsy of the metastasis had any effect on the rate of HER2 discordance. We also compared the overall survival durations of patients with HER2-concordant and -discordant tumors. Patients and Methods We retrospectively identified all patients who initially had been diagnosed with HER2-positive (immunohistochemi

APA, Harvard, Vancouver, ISO, and other styles

8

Shin, Junghoon, Ji-Yeon Kim, Jung Min Oh, et al. "Comprehensive Clinical Characterization of Decade-Long Survivors of Metastatic Breast Cancer." Cancers 15, no. 19 (2023): 4720. http://dx.doi.org/10.3390/cancers15194720.

Full text

Abstract:

Background: Elucidating the clinical features of metastatic breast cancer (MBC) patients with an exceptionally favorable prognosis may offer insights to improve the survival of more typical patients. Methods: We collected comprehensive real-world data on clinicopathologic characteristics, treatments, and outcomes of 110 consecutive MBC patients who survived for over ten years from the clinical data warehouse of Samsung Medical Center. Results: The cohort included 54 hormone receptor (HR)-positive/HER2-negative (HR+/HER2−), 21 HR+/HER2+, 16 HR−/HER2+, and 14 triple-negative breast cancer (TNBC)

APA, Harvard, Vancouver, ISO, and other styles

9

Hasan, Shaakir, Zachary Neubauer, Robert H. Press, et al. "Prognostic implications of HER2Neu-low in metastatic breast cancer." Journal of Clinical Oncology 40, no. 16_suppl (2022): 1044. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.1044.

Full text

Abstract:

1044 Background: HER2-Low (or HER2-equivocal, FISH negative) breast cancer has historically been treated as HER2-negative; however, recent evidence suggests that there may be prognostic and/or predictive differences between the two. We explore demographic characteristics and clinical outcomes of HER2-negative and HER2-low metastatic breast cancer (MBC) patients using real world data. Methods: We queried the National Cancer Database to identify MBC patients that were HER2 0, HER2 1+, or HER2 2+ per immunohistochemical staining, with the latter two defined as HER2-low and the former HER2-negativ

APA, Harvard, Vancouver, ISO, and other styles

10

Lucas, Tylan, Joshua Chan, and Neha Chopra. "Sacituzumab Govitecan for the Treatment of HR+/HER2- Breast Cancer in Heavily Pre-treated Patients." Oncology & Haematology 19, no. 1 (2023): 1. http://dx.doi.org/10.17925/ohr.2023.19.1.1.

Full text

Abstract:

Metastatic hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) breast cancer survival outcomes have improved significantly; however, once endocrine resistance develops, response rates to systemic treatments are limited. Within the developing field of antibody–drug conjugates, the TROPiCS-02 study showed a significant improvement in progression-free survival with sacituzumab govitecan compared with physician’s choice of chemotherapy in patients with endocrine-resistant, metastatic, HR+/HER2- breast cancer. Additionally, overall survival similarly improved (

APA, Harvard, Vancouver, ISO, and other styles

11

Jiang, Changchuan, Stuthi Perimbeti, Lei Deng, Charles L. Shapiro, and Shipra Gandhi. "Abstract 4124: Clinical outcomes in women with metastatic HER2-Low breast cancer in the real world." Cancer Research 82, no. 12_Supplement (2022): 4124. http://dx.doi.org/10.1158/1538-7445.am2022-4124.

Full text

Abstract:

Abstract Background: The development of novel anti-HER2 drugs opens new treatment options for patients with breast cancers, including women with lower expression of HER2. The aim of this study was to compare the clinical outcomes of HER2-low and HER2-zero metastatic breast cancer in the real world. Methods: Female patients diagnosed with metastatic breast cancer and low HER2 expression or HER2-zero expression between 2010 and 2017, and who received systematic therapy, were identified from the National Cancer Database (NCDB). The National Cancer Data Base (NCDB) is a nationwide oncology outcome

APA, Harvard, Vancouver, ISO, and other styles

12

Wang, Biyun, Shuhui You, and Yannan Zhao. "Clinicopathological characteristics, evolution, treatment patterns and outcomes of hormone-receptor-positive/HER2-low-positive metastatic breast cancer: A retrospective analysis." Journal of Clinical Oncology 41, no. 16_suppl (2023): e13058-e13058. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.e13058.

Full text

Abstract:

e13058 Background: HER2-low positivity is more prevalent in breast cancers with positive hormone receptor (HR). Patients with HR-positive and low HER2 expression may have different prognosis and characteristics. Nevertheless, research focusing on HR-positive/HER2-low-positive breast cancer remains scarce. Methods: This study included 458 patients with HR-positive/HER2-negative metastatic breast cancer (HR+/HER2- MBC) who received first- or second-line endocrine therapy at the Fudan University Shanghai Cancer Center (FUSCC) between July 2010 and October 2022. Results: Clinicopathological charac

APA, Harvard, Vancouver, ISO, and other styles

13

Aversa, Caterina, Elena Geuna, Rossella Martinello, et al. "Metastatic breast cancer subtypes and central nervous system metastases." Journal of Clinical Oncology 31, no. 15_suppl (2013): e11581-e11581. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.e11581.

Full text

Abstract:

e11581 Background: The relapse pattern, survival and response to therapy are known to be different between breast cancer (BC) subtypes defined by combining hormone-receptor (HR) and HER2 status. Our aim was to study incidence and predictors of central nervous system metastases (CNS-M) and the outcome after CNS-M according to tumor subtype. Methods: 488 patients (pts) treated with at least one line of chemotherapy for metastatic BC were retrospectively evaluated. According to the combination of HR and HER2 status, tumors were grouped in: Luminal (Lum): HR+/HER2-, Luminal/HER2+ (Lum/HER2+): HR+/

APA, Harvard, Vancouver, ISO, and other styles

14

Valencia-Espinoza, Evelyn, Emiliano Pulla-Cadmilema, Lissette P. Velez Avila, et al. "Abstract P4-07-08: IMPACT ON OVERALL SURVIVAL ACCORDING TO BREAST CANCER IMMUNOPHENOTYPES: REAL-WORLD DATA IN METASTATIC BREAST CANCER IN ECUADOR." Cancer Research 83, no. 5_Supplement (2023): P4–07–08—P4–07–08. http://dx.doi.org/10.1158/1538-7445.sabcs22-p4-07-08.

Full text

Abstract:

Abstract Background: Breast cancer immunohistochemistry subtype classification by hormone receptor has become the standard practice for therapeutic decision making. The subtype is one of the crucial factors affecting breast cancer prognostic. Despite the progress in understanding of complex mechanisms in progression of breast cancer, the treatment is a global challenge health around the world, the 5-year survival rate is 26%. Currently in develop countries, in the metastatic stage, a gain in survival in the HR+/HER2+ subtype has been evidenced, likely attributable to major advances in HER2-tar

APA, Harvard, Vancouver, ISO, and other styles

15

Chen, Mengdi, Jiayi Wu, and Li Zhu. "Correlation of hormonal receptor level and survival outcome in HER2-positive nonmetastatic breast cancer." Journal of Clinical Oncology 38, no. 15_suppl (2020): e12568-e12568. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e12568.

Full text

Abstract:

e12568 Background: In human epidermal growth factor 2 (HER2)-positive breast cancer, emerging evidences imply that clinical behavior and prognosis differ according to hormone receptor (HR) status. However, there is no conclusion about the relevance between estrogen receptor (ER) or progesterone receptor (PR) expression and clinical outcome of HER2-positive breast cancer. Our study is designed to determine the effect of different ER/PR levels on survival benefit of HER2-positive early breast cancer. Methods: 984 non-metastatic HER2-positive breast cancer patients between January 2009 and Decemb

APA, Harvard, Vancouver, ISO, and other styles

16

Gaur, Kush C., Justin Tiu-Lim, Julie McGrath, et al. "Abstract 5793: Comprehensive characterization of FGF/FGFR alterations in invasive breast cancers." Cancer Research 82, no. 12_Supplement (2022): 5793. http://dx.doi.org/10.1158/1538-7445.am2022-5793.

Full text

Abstract:

Abstract BACKGROUND FGFR signaling is central for cancer cell proliferation, migration, angiogenesis, and survival. The frequency and type of FGF/FGFR aberrations are not well-characterized across invasive breast cancer subtypes and metastatic sites of disease. In hormone receptor positive breast cancers, FGFR1 amplification correlates with early progression on endocrine therapy and promotes resistance to CDK4/6 inhibition. Our study evaluated the incidence and characterization of FGF alterations in invasive breast cancers and examined differences based on histologic subtype, molecular subtype

APA, Harvard, Vancouver, ISO, and other styles

17

Johnston, Stephen. "Abstract MS1-3: Treatment of ER+/HER2+ breast cancer." Cancer Research 83, no. 5_Supplement (2023): MS1–3—MS1–3. http://dx.doi.org/10.1158/1538-7445.sabcs22-ms1-3.

Full text

Abstract:

Abstract Co-expression of hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2) occurs in 10% of all breast cancers, and due to cross-talk mechanisms that influence cell signalling the co-expression of these receptors modulates response of these cancers to both HER2-directed and endocrine therapies. Prior to the advent of HER2 targeted therapies, patients with HR+/HER2+ breast cancer had a significantly worse prognosis compared with HR+/HER2- breast tumours, primarily related to HER2 signalling driving endocrine resistance. Likewise, prior clinical studies in the neoadjuva

APA, Harvard, Vancouver, ISO, and other styles

18

Yuan, Qianyu, Emily Castellanos, Erin Fidyk, et al. "Metastatic patterns and outcomes by HER2 and hormone receptor (HR) status in patients (pts) with metastatic breast cancer (mBC)." Journal of Clinical Oncology 41, no. 16_suppl (2023): 1031. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.1031.

Full text

Abstract:

1031 Background: HER2-low status in mBC is predictive of benefit to trastuzumab deruxutan, but whether it is biologically distinct from HER2-neg disease is unclear. To better understand the prognostic significance of HER2-low status, we assessed patterns of metastases and real world overall survival (rwOS) by HER2 and HR status. Methods: Pts with mBC diagnosis from 1/1/2011 to 5/31/2022 were selected from the nationwide deidentified Flatiron Health electronic health record (EHR)-derived database. HER2 and HR status was derived from human abstraction (IHC 0-1+/2+/3+, FISH pos/neg, ER/PR) and ma

APA, Harvard, Vancouver, ISO, and other styles

19

File, Danielle, Yara Abdou, Amy Wheless, Claire Dees, and Lisa Carey. "Abstract P1-17-05: Benefit of endocrine therapy for metastatic breast cancer after loss of hormone receptor expression in patients with HR+/HER2- primary tumors." Cancer Research 82, no. 4_Supplement (2022): P1–17–05—P1–17–05. http://dx.doi.org/10.1158/1538-7445.sabcs21-p1-17-05.

Full text

Abstract:

Abstract Background. Loss of estrogen receptor (ER) and/or progesterone receptor (PR) expression between primary breast tumors and metastases occurs in one-fourth of patients. Loss of hormone receptor (HR) expression is associated with inferior clinical outcomes however optimal treatment strategies in this setting have not been defined. Methods. Patients with HR+/HER2- primary breast tumors and subsequent HR-/HER2- metastatic biopsies, as determined by immunohistochemical staining, were identified using the University of North Carolina Metastatic Breast Cancer Clinical Database which includes

APA, Harvard, Vancouver, ISO, and other styles

20

Pribus, Sophia, Maxine C. Umeh-Garcia, Bo Gu, et al. "Abstract PO5-06-01: Loss of hormone receptor expression in breast cancer is associated with increased brain tropism and accelerated progression of leptomeningeal disease." Cancer Research 84, no. 9_Supplement (2024): PO5–06–01—PO5–06–01. http://dx.doi.org/10.1158/1538-7445.sabcs23-po5-06-01.

Full text

Abstract:

Abstract The four breast cancer subtypes—luminal A, luminal B, HER2-overexpressing, and triple-negative breast cancer (TNBC) – are classified based on gene expression profiles of hormone receptors (HRs) (estrogen receptor (ER) and progesterone receptor (PR)) and human epidermal growth factor receptor 2 (HER2/ERBB2). Negative hormone receptor status is known to be associated with more aggressive breast cancer. Compared to other breast cancer subtypes, the HR-negative TNBC and HER2-overexpressing subtypes are characterized by high rates of recurrence and a notable increase in brain metastases an

APA, Harvard, Vancouver, ISO, and other styles

21

Chen, Siying, Jin Yang, Yang Liu, Haisheng You, Yalin Dong, and Jun Lyu. "Prognostic factors and survival outcomes according to tumor subtype in patients with breast cancer lung metastases." PeerJ 7 (December 17, 2019): e8298. http://dx.doi.org/10.7717/peerj.8298.

Full text

Abstract:

Background Reports on the incidence and prognoses of lung metastases when diagnosing breast cancer patients with different subtypes are limited. Our study investigated the effect of molecular sub-typing stratification on the prognoses of lung metastatic breast caner patients. Methods Patients with breast cancer and lung metastases were identified from Surveillance, Epidemiology and End Results population-based data between 2010 and 2015. Univariate and multivariate Cox regression analyses were performed to identify risk factors and prognoses, overall survival (OS) and breast cancer-specific su

APA, Harvard, Vancouver, ISO, and other styles

22

Muñoz-Carrillo, Francisco Javier, Laia Paré, Benedetta Conte, et al. "Abstract P2-23-16: Clinico-Pathological and Molecular Characterization of HER2-Enriched Breast Tumors Independently of HER2 Status." Cancer Research 83, no. 5_Supplement (2023): P2–23–16—P2–23–16. http://dx.doi.org/10.1158/1538-7445.sabcs22-p2-23-16.

Full text

Abstract:

Abstract INTRODUCTION: Breast cancer (BC) is a highly prevalent and heterogeneous disease, entailing different so-called intrinsic subtypes (IS) according to gene expression, namely Luminal A, Luminal B, HER2-Enriched (HER2E) and Basal-like, as well as a normal breast-like group. The HER2E is still a poorly understood entity, which needs further biologic characterization to improve therapeutic management. MATERIAL AND METHODS: Patients (pts) treated at Hospital Clinic (Barcelona, Spain) over 18 years with a diagnosis of metastatic BC, with available matched primary and metastatic tumor samples

APA, Harvard, Vancouver, ISO, and other styles

23

Lauria, RN, APN, AOCNP, Jacquelyn, and Rose DiMarco, PharmD, BCPS, BCOP. "Breast Cancer: 2022 ASCO Annual Meeting Highlights for the Advanced Practitioner." Journal of the Advanced Practitioner in Oncology 13, no. 6 (2022): 570–78. http://dx.doi.org/10.6004/jadpro.2022.13.6.2.

Full text

Abstract:

Jacquelyn Lauria, RN, APN, AOCNP®, of Rutgers Cancer Institute, discusses results from the DESTINY-BREAST04 trial on HER2-low metastatic breast cancer, findings on sacituzumab govitecan in HR-positive, HER2-negative metastatic breast cancer, and options for disease progression after a CDK4/6 inhibitor. Rose DiMarco, PharmD, BCPS, BCOP, of Thomas Jefferson University Hospital, considers insights provided by a survey on participation in clinical trials among Black patients with metastatic breast cancer.

APA, Harvard, Vancouver, ISO, and other styles

24

Schmitz, Frank, Wilbert B. Copeland, Justine Dell Aringa, Kathryn Newhall, Mary L. Disis, and Sasha E. Stanton*. "Populations of Triple Negative and Hormone Receptor Positive HER2 Negative Breast Tumors Share Immune Gene Profiles." Journal of Biomedical Research & Environmental Sciences 5, no. 9 (2024): 1200–1213. http://dx.doi.org/10.37871/jbres2008.

Full text

Abstract:

Background: Immune therapy has revolutionized the treatment of certain cancers including melanoma and lung cancer. Breast cancer has fewer tumors with high immune infiltrate and Immune Checkpoint Inhibitor (ICI) therapy has shown the most significant responses in the Triple Negative (TN) subtype although roles are emerging in the other subtypes. The presence of Tumor Infiltrating Lymphocytes (TIL) is predictive of response to ICI therapy in metastatic TN and associated with better survival in local TN disease. Hormone Receptor (HR) positive HER2 negative (HR+HER2-) breast tumors do not show im

APA, Harvard, Vancouver, ISO, and other styles

25

Yijun Fan, Kevin, Rania Chehade, Italo Fernandes, Veronika Moravan, and Katarzyna Jerzak. "BMRK-05 ASSOCIATION BETWEEN HER2-LOW STATUS AND TIME TO DEVELOPMENT OF BRAIN METASTASES AMONG PATIENTS WITH BREAST CANCER: A RETROSPECTIVE COHORT STUDY." Neuro-Oncology Advances 6, Supplement_1 (2024): i9. http://dx.doi.org/10.1093/noajnl/vdae090.027.

Full text

Abstract:

Abstract BACKGROUND Brain metastases (BrM) develop in a high proportion of patients with breast cancer. We aimed to investigate the association between HER2 status (HER2-0, HER2-low, HER2+) and time to BrM development in patients treated for breast cancer BrM. METHODS We investigated a cohort of 188 women with metastatic breast cancer (MBC) treated for BrM at Sunnybrook Odette Cancer Centre from 2008-2018, for whom HER2 status was available in either the primary breast cancer (PBC) or metastatic site. We investigated: (1) association between HER2 status of the PBC (when available) and time fro

APA, Harvard, Vancouver, ISO, and other styles

26

Baclig, Nikita V., and Kelly E. McCann. "Updates in the treatment of HR+HER2- breast cancer." Current Opinion in Obstetrics & Gynecology 36, no. 1 (2023): 57–63. http://dx.doi.org/10.1097/gco.0000000000000925.

Full text

Abstract:

Purpose of review Breast cancer (BC) is the most common cancer among women in the United States and the second leading cause of cancer death. BC research, diagnostics, drug development, and expansion of therapies for novel indications advances so rapidly that BC treatment standards change month-by-month. Herein we discuss notable advancements in the past year for hormone receptor positive (HR+) HER2 negative (HER2−) BC. Recent findings Radiolabeled estradiol imaging and circulating tumor DNA (ctDNA) have changed our approach to metastatic BC (mBC) detection. Amongst an abundance of therapy opt

APA, Harvard, Vancouver, ISO, and other styles

27

Villgran, Vipin Das, Aju Mathew, Margaret Quinn Rosenzweig, et al. "Effect of tumor subtype on overall survival in brain metastatic breast cancer patients treated with cranial irradiation." Journal of Clinical Oncology 32, no. 26_suppl (2014): 74. http://dx.doi.org/10.1200/jco.2014.32.26_suppl.74.

Full text

Abstract:

74 Background: Brain metastatic breast cancer (BMBC) is often treated with whole brain radiation therapy (WBRT), stereotactic radiosurgery (SRS) or both. Breast cancer tumor subtypes defined by hormone receptor (HR) and HER2 status have an important prognostic role in metastatic disease. It is unclear if tumor subtypes have a prognostic role in patients receiving WBRT or SRS. We aimed to investigate the association between breast cancer subtype and overall survival (OS) among BMBC patients treated with WBRT and SRS. Methods: In a single-institution cohort study, BMBC patients treated with WBRT

APA, Harvard, Vancouver, ISO, and other styles

28

Narloch, Jessie, Catherine Luedke, Gloria Broadwater, et al. "Number of tumor-infiltrating lymphocytes in breast cancer brain metastases compared to matched breast primaries." Journal of Clinical Oncology 35, no. 15_suppl (2017): 2049. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.2049.

Full text

Abstract:

2049 Background: Breast cancer brain metastasis (BCBM) is frequent in advanced disease, has limited therapies, and is associated with poor prognosis. Increased stromal tumor infiltrating lymphocytes (sTILs) are prognostic in triple-negative breast cancer (TNBC) and predictive of therapeutic response in early breast cancer (BC). However, little is known about sTILs in the metastatic setting. We compared %sTILs between the largest known cohort of matched primary tumors and BCBM and correlated the results with clinical endpoints. Methods: We retrospectively investigated 37 matched primary tumors

APA, Harvard, Vancouver, ISO, and other styles

29

Cha, Chihwan, Sung Gwe Ahn, Tae-Kyung Yoo, et al. "Local Treatment in Addition to Endocrine Therapy in Hormone Receptor-Positive and HER2-Negative Oligometastatic Breast Cancer Patients: A Retrospective Multicenter Analysis." Breast Care 15, no. 4 (2019): 408–14. http://dx.doi.org/10.1159/000503847.

Full text

Abstract:

Background: Recent trials have provided robust evidence demonstrating that endocrine therapy with/without targeted therapy, such as cyclin-dependent kinase 4/6 inhibitors or mTOR (mammalian target of rapamycin) inhibitors, effectively halts disease progression in hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. We investigated the survival impact of local treatment of metastases as a first-line treatment after metastasis in HR-positive and HER2-negative breast cancer patients with a very low metastatic volume. Materials and M

APA, Harvard, Vancouver, ISO, and other styles

30

Weinmann, Sheila, Debra Ritzwoller, Marilyn Kwan, et al. "Abstract PO5-04-07: Characteristics of patients with metastatic HR+/HER2+ breast cancer in a Kaiser Permanente observational multi-site cohort." Cancer Research 84, no. 9_Supplement (2024): PO5–04–07—PO5–04–07. http://dx.doi.org/10.1158/1538-7445.sabcs23-po5-04-07.

Full text

Abstract:

Abstract Background: Approximately 10% of female breast cancer and 13% of male breast cancer tumors express hormone-receptor positive/human epidermal growth factor receptor 2 positive (HR+/HER2+) molecular subtype. Since HER2+ targeted agents were made available nearly 10 years ago, there has been limited innovation in treatment of patients with HR+/HER2+ metastatic breast cancer (mBC) to improve clinical outcomes. This study aims to characterize the HR+/HER2+ mBC patient population by describing demographic and clinical characteristics and treatment patterns in a racially diverse, insured, po

APA, Harvard, Vancouver, ISO, and other styles

31

Zhang, Jin. "Abstract PO2-08-02: Evaluation of predictive and prognostic value of androgen receptorexpression in breast cancer subtypes treated with neoadjuvantchemotherapy." Cancer Research 84, no. 9_Supplement (2024): PO2–08–02—PO2–08–02. http://dx.doi.org/10.1158/1538-7445.sabcs23-po2-08-02.

Full text

Abstract:

Abstract Background Neoadjuvant chemotherapy is the standard treatment for local advanced breast cancer administered to shrink tumors and destroy undetected metastatic cells, thereby facilitating subsequent surgery. Previous studies have shown that AR may be used as a prognostic predictor in breast cancers, but its role in neoadjuvant therapy and the relationship with prognosis of different molecular subtypes of breast cancer need to be further explored. Methods We retrospectively evaluated 1231 breast cancer patients with complete medical records at Tianjin Medical University Cancer Institute

APA, Harvard, Vancouver, ISO, and other styles

32

Garrido-Castro, Ana Christina, Liam Spurr, Melissa E. Hughes, et al. "Genomic landscape of de novo stage IV breast cancer." Journal of Clinical Oncology 37, no. 15_suppl (2019): 1022. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.1022.

Full text

Abstract:

1022 Background: Genomic profiling of primary and recurrent metastatic breast cancer (rMBC) has revealed potential resistance mechanisms to therapy. In contrast, de novo stage IV breast cancer (DNIV) represents an opportunity to elucidate metastatic drivers in the absence of treatment selection. Methods: Targeted NGS (Oncopanel, OP) using multiplexed copy number variation (CNV) and mutation (mut) detection across the full coding regions of 300 genes and selected intronic regions of 35 genes was performed on either primary or metastatic samples collected in patients (pts) with DNIV or rMBC. Mut

APA, Harvard, Vancouver, ISO, and other styles

33

Rudlowski, Christian, Nina Beermann, Lena Leitzen, and Benno Nuding. "Complete Clinical Response in Locally Advanced Metastatic de novo Breast Cancer after Front-Line Treatment with Ribociclib/Letrozole within the RIBANNA Study." Breast Care 15, no. 3 (2019): 289–93. http://dx.doi.org/10.1159/000502565.

Full text

Abstract:

Introduction: Ribociclib is an orally bioavailable cyclin-dependent kinase 4/6 inhibitor. In combination with aromatase inhibitor letrozole, it has approval for treatment of hormone receptor positive (HR+) and human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer. First-line therapy with ribociclib + letrozole significantly improves progression-free survival compared to placebo + letrozole in patients with HR+/HER2− advanced breast cancer. In patients with de novo advanced or metastatic breast cancer, ribociclib was able to provide substantial clinical benefit accord

APA, Harvard, Vancouver, ISO, and other styles

34

Ajjawi, Ismail, Alejandro Rios, Wei Wei, Tristen S. Park, and Maryam B. Lustberg. "Clinical, Sociodemographic, and Facility-Related Factors Influencing HER2-Targeted Therapy in Metastatic Hormone Receptor-Negative, HER2-Positive Breast Cancer." Cancers 17, no. 9 (2025): 1579. https://doi.org/10.3390/cancers17091579.

Full text

Abstract:

Background/Objectives: The use of HER2-targeted therapies has significantly improved survival outcomes in metastatic hormone receptor-negative, HER2-positive (HR−/HER2+) breast cancer. However, factors influencing their adoption remain unclear. This study examines clinical, sociodemographic, and facility-related determinants of HER2-targeted therapy utilization in metastatic HR−/HER2+ breast cancer. Methods: We conducted a retrospective cohort study of metastatic HR−/HER2+ breast cancer patients from the NCDB (2013–2020), categorizing them into HER2-targeted therapy recipients and non-recipien

APA, Harvard, Vancouver, ISO, and other styles

35

Ahmed, Talal, Mark Carty, Kaveri Nadhamuni, and Raphael Pelossof. "Abstract PO5-24-03: Breast cancer intrinsic subtypes predict outcomes in primary and metastatic samples." Cancer Research 84, no. 9_Supplement (2024): PO5–24–03—PO5–24–03. http://dx.doi.org/10.1158/1538-7445.sabcs23-po5-24-03.

Full text

Abstract:

Abstract Background: The prognostic and predictive value of the PAM50 intrinsic subtypes, namely Luminal A, Luminal B, Her2, and Basal-like subtypes, is well-studied in primary as well as metastatic breast cancer settings. Prosigna has emerged as a rapid PAM50 subtype predictor based on the NanoString nCounter assay. However, assay reproducibility across various RNASeq or qRT-PCR platforms can be challenging, especially when applying the predictor on metastatic breast cancer tumors. Here, we used SpinAdapt to create an intrinsic subtype predictor that works on RNA sequencing data, and validate

APA, Harvard, Vancouver, ISO, and other styles

36

Gilbert, Aidan, Courtney Williams, Pravinkumar Kandhare, et al. "Visualizing treatment patterns and survival in metastatic breast cancer." Journal of Clinical Oncology 37, no. 27_suppl (2019): 316. http://dx.doi.org/10.1200/jco.2019.37.27_suppl.316.

Full text

Abstract:

316 Background: Optimal treatment sequencing (i.e., the order in which drugs are given) for metastatic breast cancer (MBC) is unknown. We aimed to develop an approach to visualize treatment patterns and survival in MBC. Methods: This retrospective study utilized ASCO’s CancerLinQ Discovery® database generated from electronic health records. Subjects included 3,312 women aged ≥18 years who were diagnosed with and received treatment for MBC after 1980. Hormone receptor (HR) status was determined by concordant diagnosis and treatment records. Human epidermal growth factor (HER2) status was determ

APA, Harvard, Vancouver, ISO, and other styles

37

Seffar, Evan, Brooke Mastrogiacomo, Alex Paynter, et al. "Abstract 1118: The GENIE BPC BRCA Cohort: a real-world repository of standardized clinical and genomic data for young patients with breast cancer." Cancer Research 85, no. 8_Supplement_1 (2025): 1118. https://doi.org/10.1158/1538-7445.am2025-1118.

Full text

Abstract:

Abstract Purpose: The first comprehensive analysis of the detailed clinico-genomic landscape of the breast cancer (BC) cohort of the American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) Biopharma Collaborative (BPC). Methods: We analyzed 1, 045 BC patients treated at three GENIE-participating institutions. Breast cancer patients in the GENIE registry aged 18-56 at sequencing and with tumor(s) sequenced between 2013 and 2018 were randomly chosen for curation using the PRISSMM framework. Sites of distant metastasis were captured from im

APA, Harvard, Vancouver, ISO, and other styles

38

Kidd, Michael, Nina J. Karlin, and Amylou C. Dueck. "Metastatic breast cancer and the elderly: A single institution, retrospective review." Journal of Clinical Oncology 30, no. 27_suppl (2012): 55. http://dx.doi.org/10.1200/jco.2012.30.27_suppl.55.

Full text

Abstract:

55 Background: The aim of this retrospective study was to examine the overall survival (OS) of metastatic breast cancer patients over a decade and assess for any differences with respect to age, tumor characteristics, and ECOG status. Methods: Data on metastatic breast cancer cases from 1999-2010 were retrieved from the institutional cancer registry and linked to electronic medical records. Through chart review of 240 metastatic breast cancer cases, we determined hormone receptor (HR), HER2/neu (HER2), ECOG, age at diagnosis of metastatic cancer and mortality data. Kaplan-Meier survival curves

APA, Harvard, Vancouver, ISO, and other styles

39

Jaber Chehayeb, Rachel, Annette Hood, Sarah Schellhorn Mougalian, et al. "Treatment patterns and medical costs of metastatic breast cancer care in the United States." Journal of Clinical Oncology 40, no. 16_suppl (2022): e18834-e18834. http://dx.doi.org/10.1200/jco.2022.40.16_suppl.e18834.

Full text

Abstract:

e18834 Background: Substantial advances in treatment of metastatic breast cancer (mBC) have led to changes in clinical practice and treatment costs in the United States in the past decade. We aimed to identify treatment patterns in mBC patients by subgroup and year after mBC diagnosis and associated costs from payer and societal perspectives. Methods: This study used the nationwide Flatiron Health electronic health record (EHR)-derived de-identified database (1/2011-5/2021). We excluded cases that were male, had < 6 months of follow up, no treatment data, no structured data within 90 days o

APA, Harvard, Vancouver, ISO, and other styles

40

Rasyid, Fahmi, Dhyka Alloyna, and Kamal Basri. "Overview of Patients with Metastatic Brain Tumors from Breast Cancer at H. Adam Malik Hospital, Medan in 2017-2021." Asian Australasian Neuro and Health Science Journal (AANHS-J) 3, no. 3 (2021): 12–19. http://dx.doi.org/10.32734/aanhsj.v3i3.7581.

Full text

Abstract:

Abstract Introduction: The incidence of breast cancer based on Globocan in 2018, reached 2,088,849 cases (11.6%), with a mortality rate of 626,679 cases (6.6%). Breast cancer is one of the most common causes of a metastatic brain tumor. Approximately 10%-16% of patients with breast cancer develop brain metastases during the course of their disease. Current case management guidelines for patients with metastatic brain tumors from breast cancer are radiotherapy to the entire brain, with or without surgical resection, or stereotactic radiosurgery. Hormone receptor ([HR]; estrogen receptor [

APA, Harvard, Vancouver, ISO, and other styles

41

Juan, Jin, Bin Li, Biyun Wang, Zhonghua Tao, and Xichun Hu. "Clinical features, genomic landscapes, and survival outcomes of HER2-low breast cancer." Journal of Clinical Oncology 41, no. 16_suppl (2023): 1027. http://dx.doi.org/10.1200/jco.2023.41.16_suppl.1027.

Full text

Abstract:

1027 Background: Novel human epidermal growth factor receptor 2 (HER2)-directed antibody‒drug conjugates prompt the identification of the HER2-low subtype. To investigate whether HER2-low breast cancer can be defined as a distinct biological subtype, our study conducted a comprehensive analysis on the clinical and molecular features among patients with different HER2 statuses. Methods: Clinical and genomic data of 579 metastatic breast cancer patients were reviewed from our next-generation sequencing (NGS) database. Genomic data of breast tumor samples was generated by targeted NGS using a can

APA, Harvard, Vancouver, ISO, and other styles

42

Schneeweiss, Andreas, Ingo Bauerfeind, Tanja Fehm, et al. "Therapy Algorithms for the Diagnosis and Treatment of Patients with Early and Advanced Breast Cancer." Breast Care 15, no. 6 (2020): 608–18. http://dx.doi.org/10.1159/000511925.

Full text

Abstract:

<b><i>Background:</i></b> In order to offer optimal treatment approaches based on available evidence, the Commission Breast of the Working Group Gynecologic Oncology (AGO) of the German Cancer Society developed therapy algorithms for eight complex treatment situations in primary and advanced breast cancer. <b><i>Summary:</i></b> Therapy algorithms for the following complex treatment situations are outlined in this paper: (neo)adjuvant therapy of human epidermal growth factor receptor 2 (HER2)-positive breast cancer; axillary surgery and neoadjuva

APA, Harvard, Vancouver, ISO, and other styles

43

Hamdard, Jamshid, Mehmet Haluk Yücel, Harun Muğlu, et al. "Clinical Outcomes in Early-Stage HER2-Low and HER2-Zero Breast Cancer: Single-Center Experience." Journal of Clinical Medicine 14, no. 9 (2025): 2937. https://doi.org/10.3390/jcm14092937.

Full text

Abstract:

Background/Objectives: The goal of this study is to characterize the survival patterns and outcomes of women with early-stage breast cancer, with a particular emphasis on the distinction between HER2-low and HER2-zero expression. There is limited real-world data on how patients with HER2-negative or HER2-low metastatic or recurrent breast cancer are treated. Methods: We retrospectively analyzed the medical records of 1500 breast cancer patients diagnosed between January 2020 and December 2024. From this cohort, 99 patients with HER2-low and 34 patients with HER2-zero early-stage breast cancer

APA, Harvard, Vancouver, ISO, and other styles

44

Araya, Carla, Bárbara Mino, Patricio Le Cerf, Fancy Gaete, Ricardo Armisen, and Daniel E. Carvajal-Hausdorf. "Molecular Analysis of PIK3CA in Metastatic Hormone Receptor-Positive Breast Cancer in Chile: Clinical and Pathological Insights." International Journal of Molecular Sciences 25, no. 22 (2024): 12246. http://dx.doi.org/10.3390/ijms252212246.

Full text

Abstract:

Breast cancer is the most common cancer among women and a leading cause of cancer-related deaths. PIK3CA gene mutations, which are often present in advanced HR+ breast cancer, can be targeted by alpelisib. However, data on PIK3CA mutations in Chile are limited. Here, we aim to assess the mutational status of PIK3CA in metastatic breast cancer tissues from Chilean patients and describe their clinicopathological characteristics and survival outcomes. We analyzed 102 formalin-fixed, paraffin-embedded metastatic breast cancer samples from 96 patients diagnosed at three Chilean hospitals between 20

APA, Harvard, Vancouver, ISO, and other styles

45

Kahraman, Seda, Mutlu Hızal, Özge Gümüşay, et al. "HER2-low expression in patients with hormone receptor positive and HER2 negative advanced breast cancer treated with ribociclib or palbociclib in combination with endocrine therapy." Turkish Journal of Clinics and Laboratory 16, no. 2 (2025): 255–62. https://doi.org/10.18663/tjcl.1639022.

Full text

Abstract:

Aim: Hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative breast cancer which represents the most common subgroup of metastatic breast cancer (MBC). Recently, further subclassification for HER2-negative tumors has emerged as HER2-low. There is limited knowledge regarding the effect of HER2-low expression on outcomes of patients with HR-positive and HER2-negative MBC treated with CDK 4/6 inhibitors plus hormonal therapy. Therefore, we evaluated survival parameters according to HER2-low status for this patient group in this study. Material and Methods: As the Turkish O

APA, Harvard, Vancouver, ISO, and other styles

46

Meegdes, Marissa, Khava I. E. Ibragimova, Dorien J. A. Lobbezoo, et al. "The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry." Breast Cancer Research and Treatment 192, no. 2 (2022): 331–42. http://dx.doi.org/10.1007/s10549-021-06472-5.

Full text

Abstract:

Abstract Purpose The hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) are the main parameters in guiding systemic treatment choices in breast cancer, but can change during the disease course. This study aims to evaluate the biopsy rate and receptor subtype discordance rate in patients diagnosed with advanced breast cancer (ABC). Methods Patients diagnosed with ABC in seven hospitals in 2007–2018 were selected from the SOutheast Netherlands Advanced BREast cancer (SONABRE) registry. Multivariable logistic regression analyses were performed to identify factors influencin

APA, Harvard, Vancouver, ISO, and other styles

47

He, Dong-Jie, De-Quan Yu, Qi-Ming Wang, et al. "Breast Cancer Subtypes and Mortality of Breast Cancer Patients With Brain Metastasis at Diagnosis: A Population-Based Study." INQUIRY: The Journal of Health Care Organization, Provision, and Financing 58 (January 2021): 004695802110556. http://dx.doi.org/10.1177/00469580211055636.

Full text

Abstract:

Background Brain metastasis is an important cause of breast cancer-related death. Aim We evaluated the relationships between breast cancer subtype and prognosis among patients with brain metastasis at the initial diagnosis. Methods The Surveillance, Epidemiology, and End Results database was searched to identify patients with brain metastasis from breast cancer between 2010 and 2015. Multivariable Cox proportional hazard models were used to identify factors that were associated with survival among patients with initial brain metastases. The Kaplan–Meier method was used to compare survival outc

APA, Harvard, Vancouver, ISO, and other styles

48

Kaklamani, V. G., J. Cicconi, W. Gradishar, et al. "Increased HER2 expression in women with recurrent ER positive breast cancer." Journal of Clinical Oncology 25, no. 18_suppl (2007): 10516. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.10516.

Full text

Abstract:

10516 Introduction: Tamoxifen (TAM) remains widely used in the treatment of all stages of breast cancer. Although the majority of hormone receptor (HR) positive tumors respond to TAM, many of these breast cancers will develop resistance resulting in disease recurrence or progression. Over-expression of HER2 appears to play a role in de novo tamoxifen-resistance. We have demonstrated previously that HR-positive breast cancers exposed to selective estrogen receptor modulators (SERMs), such as tamoxifen, in vivo continue to express HR but have an increase in the expression of HER2 (O'Regan Clin C

APA, Harvard, Vancouver, ISO, and other styles

49

Lee, Kyoung Eun, Ahrong Ham, Sewon Lee, et al. "Abstract PO4-05-11: Effects of body mass index on the treatment outcome of patients with metastatic breast cancer in the real world." Cancer Research 84, no. 9_Supplement (2024): PO4–05–11—PO4–05–11. http://dx.doi.org/10.1158/1538-7445.sabcs23-po4-05-11.

Full text

Abstract:

Abstract Purpose: Metastatic/recurrent breast cancer has a relatively long survival compared to other cancers and depending on the biologic subtype, the treatment outcome is different. In general, obesity or overweight is associated with poor prognosis of breast cancer, but the relationship between body mass index (BMI) and prognosis in metastatic cases is not clear. The aim of this study is investigating the effect of BMI on survival outcome through long-term follow-up in single institution, retrospectively. Method: This study included the patients with metastatic/recurrent breast cancer who

APA, Harvard, Vancouver, ISO, and other styles

50

Zhou, Yi-Fan, Hu-Yun-Long Zhang, Xi Jin, Yi-Zhou Jiang, and Zhi-Ming Shao. "Abstract PO1-15-09: Vitamin A Metabolism Induces Ferroptosis to Enhance Immune Therapy Efficacy in HR+/HER2- Breast Cancer." Cancer Research 84, no. 9_Supplement (2024): PO1–15–09—PO1–15–09. http://dx.doi.org/10.1158/1538-7445.sabcs23-po1-15-09.

Full text

Abstract:

Abstract Background: Immune checkpoint blockade (ICB) has substantially improved patient overall and progression-free survival in triple-negative breast cancer (TNBC), but its efficacy remains to be elucidated in the hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer, which is characterized by generally impotent lymphocytic infiltration. In the I-SPY2 trial (NCT01042379), pembrolizumab- or durvalumab-containing neoadjuvant therapy increased the pathologic complete response of HR+/HER2- patients. However, pembrolizumab-containing therapy fail

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!